New PET tracer aims to spot hidden amyloid deposits

NCT ID NCT07232459

Recruiting now Diagnosis Sponsor: Tianjin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new imaging agent called [18F]FT8 to see if it can help doctors better see and diagnose amyloidosis, a disease where abnormal proteins build up in organs like the heart. The study will involve 20 patients with amyloidosis and 5 healthy volunteers. Researchers will compare the new PET scan results with standard tests like echocardiograms and MRIs to check if it is safe and more accurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Amyloid Neuropathies, Familial amyloidosis primary systemic amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID AMYLOIDOSIS CARDIAC AMYLOIDOSIS HEALTHY SUBJECTS

Contacts and locations

Locations

The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, Anhui, 230000, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, Tianjin Municipality, 350005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.